This HTML5 document contains 125 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
p	http://www.wikidata.org/prop/
wikibase	http://wikiba.se/ontology#
n12	http://dx.doi.org/10.1200/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q34743609

rdf:type

wikibase:Item

schema:description

scientific article artículo científico publicado en 2008 artículu científicu espublizáu en 2008 2008年論文 wetenschappelijk artikel vitenskapelig artikkel 2008년 논문 2008 nî lūn-bûn artigo científico bilimsel makale مقالة علمية bài báo khoa học 2008年论文 teaduslik artikkel מאמר מדעי 2008年论文 научная статья artigo científico (publicado na 2008) мақолаи илмӣ scienca artikolo articolo scientifico artikull shkencor επιστημονικό άρθρο 2008年論文 naučni članak vitskapeleg artikkel 2008年の論文 სამეცნიერო სტატია mokslinis straipsnis artykuł naukowy vedecký článok научни чланак 2008 թվականի փետրվարին հրատարակված գիտական հոդված 2008年论文 научни чланак article científic บทความทางวิทยาศาสตร์ vetenskaplig artikel wissenschaftlicher Artikel 2008年论文 article scientifique (publié 2008) 2008年論文 vědecký článek наукова стаття, опублікована в лютому 2008 videnskabelig artikel (udgivet 2008) artikulong pang-agham articol științific article scientific tudományos cikk мақолаи илмӣ tieteellinen artikkeli 2008年論文 سائنسی مضمون 2008年论文 مقالهٔ علمی ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научна статия artigo científico (publicado na 2008) 2008年论文 2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած 2008年論文

p:P577

wds:Q34743609-583304F2-70AD-48D8-883A-454103573469

wdt:P577

2008-02-01T00:00:00Z

p:P407

wds:Q34743609-5E28391B-CEBF-408C-8CB2-679C63C891C8

wdt:P407

wd:Q1860

p:P2093

wds:Q34743609-C1CBEB41-6A78-46A3-9F2B-7DFED58A24BA wds:Q34743609-E32D8060-8F6C-4B1E-BBEE-D36A669B2E37 wds:Q34743609-94D842DE-91F4-4191-BEE6-234D65A2EC27 wds:Q34743609-8EFFD8E2-EB85-4B6B-A3A2-CBC395979E12 wds:Q34743609-949B249C-E92C-41BB-9F53-54D1DDCE1901 wds:Q34743609-A2956F6B-5324-4B10-8F05-4891CDCFF2BA wds:Q34743609-A3849C6E-FD28-469A-A61E-9AE693CC2CB4 wds:Q34743609-0BD62328-0B1E-4C21-97EB-3C131982E0D0

wdt:P2093

Christopher D M Fletcher Daniela Heinz Charles D Blanke Christopher L Corless Peter J Roberts Jonathan A Fletcher Elisabeth Wehre Burton Eisenberg

rdfs:label

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

skos:prefLabel

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

schema:name

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

p:P50

wds:Q34743609-AA24C9F1-D63F-43E8-8CEE-91690E5DBF86 wds:Q34743609-C9CE5515-EC0A-4056-A188-AAC6CDF5C3E5 wds:Q34743609-58B72AB9-E438-47E7-B619-06B65D15E6CC wds:Q34743609-60EE0C98-0D15-4132-A992-E6D7D7841372 wds:Q34743609-6D752C74-B412-4067-BC7A-4B1FC7C0D3AF

wdt:P50

wd:Q16299408 wd:Q125317475 wd:Q96229532 wd:Q66809438 wd:Q40526741

p:P1476

wds:Q34743609-C43BB2FA-539B-421A-811C-6C6FD13E62FA

wdt:P1476

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT

p:P304

wds:Q34743609-85D0D7AC-FAAE-46E1-B184-12786F2517F0

wdt:P304

620-625

p:P31

wds:Q34743609-DB12D281-1682-42FA-8D76-2BADF19A2655

wdt:P31

wd:Q13442814

p:P921

wds:Q34743609-9D61672A-87FE-4AAC-931C-9416740FCE7A wds:Q34743609-C3DBDBF2-AE05-4C3B-B397-0D1C3BE4A1EE

wdt:P921

wd:Q177094 wd:Q42824440

p:P698

wds:Q34743609-ED713DAB-6DBB-47A9-806D-44896A9E5222

wdtn:P698

n11:18235121

wdt:P698

18235121

p:P1433

wds:Q34743609-B424418E-AEC9-479D-90A7-F196CA19215B

wdt:P1433

wd:Q400292

p:P433

wds:Q34743609-7C43D465-89D3-4C53-8B0A-27A6D4E0F2FB

p:P478

wds:Q34743609-0EFE88C5-6F7A-43FD-BB2F-3BB85B244457

wdt:P433

4

wdt:P478

26

p:P356

wds:Q34743609-66731F4A-256D-4A05-9390-AFCF4DD6E803

wdtn:P356

n12:JCO.2007.13.4403

wdt:P356

10.1200/JCO.2007.13.4403

p:P5875

wds:Q34743609-809BBF3B-2806-4D99-9C3F-67FEF637A8E6

wdt:P5875

5617122